Zozaya González N, Alcalá Revilla B, Arrazola Martínez P, Chávarri Bravo J R, Cuesta Esteve I, García Rojas A J, Martinón-Torres F, Redondo Margüello E, Rivero Cuadrado A, Tamames Gómez S, Villaseca Carmena J, Hidalgo-Vega A
Health Economics Department, Weber , Madrid, Spain.
University of Las Palmas de Gran Canaria , Las Palmas, Spain.
Hum Vaccin Immunother. 2020 Nov 1;16(11):2873-2884. doi: 10.1080/21645515.2020.1732164. Epub 2020 Apr 3.
: To advance the development of an ideal and sustainable framework agreement for the public procurement of vaccines in Spain, and to agree on the desirable award criteria and their relative weight. : A multidisciplinary committee of seven health-care professionals and managers developed a partial multi-criteria decision analysis to determine the award criteria that should be considered and their specific weights for the public procurement of routine vaccines and seasonal influenza vaccines, considering their legal viability. A re-test of the results was carried out. The current situation was analyzed through 118 tender specifications and compared to the ideal framework. : Price is the prevailing award criterion for the public procurement of both routine (weighting of 60% versus 40% for all other criteria) and influenza (36% versus 64%) vaccines. Ideally, 22 criteria should be considered for routine vaccines, grouped and weighted into five domains: efficacy (weighting of 29%), economic aspects (27%), vaccine characteristics (22%), presentation form and packaging (13%), and others (9%). Per criteria set, price was the most important criterion (22%), followed by effectiveness (9%), and composition/formulation (7%). Regarding influenza vaccines, 20 criteria were selected, grouped, and weighted: efficacy (29%), economic aspects (25%), vaccine characteristics (20%), presentation form and packaging (16%), and others (11%). Per criteria set, price was also the most relevant criterion (19%), followed by composition/formulation (8%), and effectiveness (8%). : Contrary to the current approach, technical award criteria should prevail over economic criteria in an ideal and sustainable framework agreement for the public procurement of vaccines.
为推动西班牙疫苗公共采购理想且可持续的框架协议的发展，并就理想的授标标准及其相对权重达成一致。一个由七名医疗保健专业人员和管理人员组成的多学科委员会开展了部分多标准决策分析，以确定在考虑法律可行性的情况下，常规疫苗和季节性流感疫苗公共采购应考虑的授标标准及其具体权重。对结果进行了重新测试。通过118份招标文件分析了当前情况，并与理想框架进行了比较。在常规疫苗（其他所有标准的权重为40%，价格权重为60%）和流感疫苗（价格权重为36%，其他为64%）的公共采购中，价格是主要的授标标准。理想情况下，常规疫苗应考虑22项标准，分为五个领域并加权：效力（权重为29%）、经济方面（27%）、疫苗特性（22%）、剂型和包装（13%）以及其他（9%）。在每个标准组中，价格是最重要的标准（22%），其次是有效性（9%）和成分/配方（7%）。对于流感疫苗，选择了20项标准，进行分组并加权：效力（29%）、经济方面（25%）、疫苗特性（20%）、剂型和包装（16%）以及其他（11%）。在每个标准组中，价格也是最相关的标准（19%），其次是成分/配方（8%）和有效性（8%）。与当前方法相反，在理想且可持续的疫苗公共采购框架协议中，技术授标标准应优先于经济标准。
